Holen Sie sich die Stockscreener-App
138.66
0.78%
0.955
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons - The Motley Fool
Dow closes sharply lower as oil surge fuels inflation fears - Proactive financial news
Dow slides as oil nears $100, US-Canada trade tensions escalate - Proactive financial news
Amgen Stock Eyes Worst Day Since 2000 on Novartis Lp(a) FailureAmgen (NASDAQ:AMGN) - Benzinga
Novartis stock falls sharply after third late-stage trial failure in a week - AD HOC NEWS
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial - Proactive financial news
Market movers: Novartis, Qualcomm, EchoStar, BioVie... - Proactive financial news
Dow Jones, S&P 500 futures indicate gap-down open while Nasdaq set for flat start; Novartis, Amgen, others to watch - upstox.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Novartis shares fall after second major trial setback in days - The Globe and Mail
Novartis shares plunge 10% as failed drug trial clouds growth outlook - Investing.com Nigeria
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Why is Novartis stock sliding today? - Investing.com
Novartis shares fall after heart drug fails late-stage trial - in.investing.com
Novartis shares fall after heart drug fails late-stage trial By Investing.com - Investing.com Canada
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Novartis stock slips as Jefferies and UBS stay neutral after Hybrozyme deal - AD HOC NEWS
Novartis stock gains as remibrutinib data and Fabhalta growth offset cell therapy trial pause - AD HOC NEWS
Novartis Up 5.6% After MS Pill Gains $3 Billion Sales Potential - TechStock²
Novartis stock gains as remibrutinib MS data offsets CAR T trial pause - AD HOC NEWS
Why Is Novartis Stock Soaring Tuesday?Novartis (NYSE:NVS) - Benzinga
Novartis remibrutinib cuts MS relapse rates in Phase 3 - grafa.com
US markets today: Dow, S&P 500, Nasdaq futures indicate gap-down open; Novartis, Duolingo, energy stocks to watch - Upstox
Novartis shares rise after multiple sclerosis drug hits late-stage trial goals - Investing.com Australia
Novartis stock steadies after pause of autoimmune cell therapy trials - AD HOC NEWS
Novartis stock trades mixed as investors weigh post-earnings outlook - AD HOC NEWS
Novartis stock trades below consensus target as post-earnings digestion continues - AD HOC NEWS
Novartis stock holds steady as investors digest latest 2026 earnings and guidance - AD HOC NEWS
Novartis stock holds steady as oncology and Alzheimer’s pipeline draws attention - AD HOC NEWS
Novartis AGADR Key Financial Ratios – Valuation, Profitability & More - Value Research
Novartis stock edges lower as investors look past recent FDA win - AD HOC NEWS
India Central Nervous System Therapeutic Market Outlook, 2033 - Grand View Research
Novartis stock holds firm after Q2 2026 growth and dual listing support - AD HOC NEWS
Alibaba Group ADR shares decline over 4% during pre-market hours; focus on AI plans after $10 billion new issue - upstox.com
Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors - ChartMill
Novartis stock extends its rally as investors weigh valuation and cardiovascular data plans - Ad-hoc-news.de
Novartis stock holds above $150 after orphan drug update - Ad-hoc-news.de
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says - Sahm
Novartis stock holds above $150 as orphan drug milestone and earnings strength support valuation - Ad-hoc-news.de
Novartis AG Sponsored ADR Revenue Breakdown – MUN:NOTA - TradingView
Novartis stock slips after UK patent win and strong Q2 2026 - Ad-hoc-news.de
Novartis stock slips from recent highs as investors digest latest quarter - Ad-hoc-news.de
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis (NYSE:NVS): A Top Dividend Stock with Strong Fundamentals and Sustainable Payouts - ChartMill
Dow Jones surges 1% despite NASDAQ decline amid chip stock sell-off - Upstox
Weekly Recap: Novartis Q2 net sales up ~1–3% and Entresto 50% sales drop - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Revenue Breakdown – BCBA:NVSB - TradingView
Novartis AG Sponsored ADR Revenue Breakdown – SWB:NOTA - TradingView
Novartis stock trades steady as Q1 2026 revenue grows and Cosentyx expansion supports outlook - Ad-hoc-news.de
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline - Sahm
Novartis stock trades steady as Q2 2026 results highlight solid specialty medicines growth - Ad-hoc-news.de
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - GlobeNewswire Inc.
Novartis ADR earnings beat by $0.23, revenue topped estimates - Investing.com Canada
Novartis AG Stock (NVS) Moved Up by 3.42% on Jul 21: Key Drivers Unveiled - TradingKey
Novartis second quarter sales rise 3% to $14.4 billion - grafa.com
0.82%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):